


FIGURE 1



Ab	Apparent Kd (nM); FACS
CD166-M9_vK1/HcB	2.39
CD166-M9_vK2/HcB	1.79
CD166-M9_vK3a/HcB	2.88
CD166-M9_vK3b/HcB	2.61
CD166-M9_vK1/HcC	3.26
CD166-M9_vK2/HcC	2.50
CD166-M9_vK3a/HcC	3.76
CD166-M9_vK3b/HcC	3.19
CD166-M9_chimera	1.12


FIGURE 2

FIGURE 3A




FIGURE 3B




FIGURE 4





FIGURE 5






FIGURE 8A

FIGURE 8B

Normal stomach





FIGURE 8C

FIGURE 8D

Normal bladder







FIGURE 9



8/26


FIGURE 10
HCC1806 tumor model




CD166 AADC Beats Benchmark Standard For Efficacy

FIGURE 11


H292 tumor model



9/26

FIGURE 12**FIGURE 13**

ELISA – Cyno and human binding are identical



10/26

FIGURE 14





FIGURE 15



12/26



FIGURE 16A**FIGURE 16B**


FIGURE 16C

FIGURE 17




FIGURE 18






FIGURE 19A

A




B

FIGURE 19B



C

FIGURE 19C



18/26

FIGURE 20A





FIGURE 20B



19/26

FIGURE 21A
TNF α





FIGURE 21B
IL-2







FIGURE 22




FIGURE 23




FIGURE 24A (HEC-1-A cells)




FIGURE 24B (AN3-CA cells)




FIGURE 24C (KLE cells)





FIGURE 24D



25/26



FIGURE 25A**FIGURE 25B**

FIGURE 26

131209127 v1

